XZP-6019

N/A

Report date: 2026/01/06 16:22:32
NME

Base Information

Drug NameXZP-6019
Drug Alias NameXZP-6019片XZP-6019
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKetohexokinase inhibitors
TargetsKetohexokinase
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Inactive CompaniesXuanzhu (HK) Biopharmaceutical Ltd
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A